A recent survey conducted by the HIV Medicine Association identified barriers to implementation of long-acting injectables ...
It was a busy week for the biotech sector. While the fourth-quarter earnings season is nearing the end, other pipeline and regulatory updates were in focus. Recap of the Week’s ...
Zacks.com on MSN6h
Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDAIt was a busy week for the biotech sector. While the fourth-quarter earnings season is nearing the end, other pipeline and ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...
A groundbreaking injectable designed to curb the global spread of HIV is now at risk of being delayed due to Donald Trump's ...
Investing.com -- Morgan Stanley expects the FDA to approve Gilead Sciences (NASDAQ: GILD )' Lenacapavir (LEN) for HIV ...
Gilead Sciences has announced EMA validation for a parallel accelerated review of lenacapavir’s MAA and EU-M4all applications ...
Foster City, California Tuesday, February 25, 2025, 16:00 Hrs [IST] ...
The discussion ended with a bold call to action for businesses, healthcare providers, and policymakers: health equity must be a priority—not just ethically, but economically. As Burgess put it: “This ...
The EMA is set to perform accelerated reviews of Gilead Sciences’ applications for its twice-yearly injectable for HIV ...
Missed KHOU 11+’s live Q&A on injectable PrEP? Watch on demand as experts discuss this HIV prevention breakthrough and answer ...
In a remarkable convergence of ancient spiritual traditions and rare celestial phenomena, millions of seekers worldwide are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback